Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Leave a Reply

Your email address will not be published. Required fields are marked *